Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

86%

6 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

5(83.3%)

Phase 4

1(16.7%)

6Total

Phase 3(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03792620Phase 3Unknown

Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation

Role: lead

NCT03402295Phase 3Completed

Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

Role: lead

NCT03207789Unknown

T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients

Role: lead

NCT02238288Phase 4Unknown

Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients

Role: lead

NCT01699412Phase 3Completed

Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease

Role: lead

NCT01532856Phase 3Unknown

Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years

Role: lead

NCT01296503Phase 3Completed

Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma

Role: lead

All 7 trials loaded